Portal de Periódicos da CAPES

Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome

2009; Elsevier BV; Volume: 91; Issue: 3 Linguagem: Inglês

10.1016/j.radonc.2009.02.011

1879-0887

Noëlle C. van der Voort van Zyp, Jean‐Briac Prévost, Mischa S. Hoogeman, J. Praag, Bronno van der Holt, Peter C. Levendag, Robertus J. van Klaveren, Peter M. T. Pattynama, Joost J. Nuyttens,

Medical Imaging Techniques and Applications

Purpose To report the clinical outcome of treatment using real-time tumor tracking for 70 patients with inoperable stage I non-small cell lung cancer (NSCLC). Materials and methods Seventy inoperable patients with peripherally located early-stage NSCLC were treated with 45 or 60 Gy in three fractions using CyberKnife. Pathology was available in 51% of patients. Thirty-nine patients had a T1-tumor and 31 had a T2-tumor. Markers were placed using the vascular, percutaneous intra-, or extra-pulmonary approach, depending on the risk of pneumothorax. Results The actuarial 2-year local control rate for patients treated with 60 Gy was 96%, compared to 78% for patients treated with a total dose of 45 Gy (p = 0.197). All local recurrences (n = 4) occurred in patients with T2-tumors. Overall survival for the whole group at two years was 62% and the cause specific survival was 85%. The median follow-up was 15 months. Grade 3 toxicity occurred in two patients (3%) after marker placement. Treatment-related late grade 3 toxicity occurred in 7 patients (10%). No grade ⩾4 toxicity occurred. Conclusion Excellent local control of 96% at 1- and 2-years was achieved using 60 Gy in three fractions for NSCLC patients treated with the real-time tumor tracking. Toxicity was low.